Advanced BioDesign announces
Two months after the start of "ODYSSEY”, the first-in-human clinical trial targeting acute myeloid leukaemia, Advanced BioDesign has signed an agreement with its historical shareholder, Xerys Invest, for a capital injection of 14.3 million euros.
Read more
Science
ALDH FAMILY
Aldehyde Dehydrogenases (ALDHs) belong to a family of enzymes that play a key role in the metabolism of endogenous and exogenous aldehydes. This group of intracellular enzymes plays a pivotal role in embryogenesis and cell differentiation as well as in cancer progression by mediating retinoic acid signalling. Their functional activity also extends to cellular redox homeostasis via detoxification of reactive aldehydes derived from lipid peroxidation and other metabolic processes thus, playing a major cytoprotective role in cells.
MECHANISM OF ACTION
ABD-3001 A FIRST-IN-CLASS INHIBITOR
ABD-3001 is a suicidal inhibitor of ALDH1 and 3. It blocks the enzyme activity irreversibly causing rapid accumulation of reactive aldehydes in tumour cells, beyond critical threshold. The accumulated aldehydes, notably HNE and MDA form genotoxic adducts with protein and DNA affecting the oncogenic signalling pathways that participate in cell proliferation.
Our vision
Advanced Biodesign
Based on our expertise in cancer metabolism and know-how in specific cell death called “apoptosis”, we will develop a new way to treat cancer to overcome actual stratification of cancer to bring new hope for patient. By focusing on rare or bad-prognostic cancer, Advanced BioDesign offer innovative therapy to target markets with high unmet medical needs in cancer.
News
Advanced BioDesign announces 14.3 million euros of additional funding from its main shareholder Xerys Invest
Two months after the start of "ODYSSEY”, the first-in-human clinical trial targeting acute myeloid leukaemia, Advanced BioDesign has signed an agreement with its historical shareholder, Xerys Invest, for a capital injection of 14.3 million euros.
Advanced Biodesign announces the start of the First-In-Human Clinical Trial "ODYSSEY" targeting Acute Myeloid Leukaemia
After receiving an approval from the National Agency for Medicinal Safety and Health Products (ANSM), Advanced BioDesign announces today the enrolment of the first patient in its "ODYSSEY" (NCT05601726) First-In-Human clinical trial in acute myeloid leukemia (AML).